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Abstract
Background—Although magnesium is important in the biology of blood pressure regulation, 
little clinical data exist on the association of hypermagnesemia and blood pressure.
Method—We examined the association of hypermagnesemia and SBP in a cross-sectional study 
of 10 521 ICU patients from a single tertiary care medical center, 6% of whom had a serum 
magnesium above 2.6 mg/dl at time of admission.
Results—In a multivariable analysis, hypermagnesemia was associated with SBP 6.2 mmHg 
lower [95% confidence interval (CI) −8.2, −4.2, P <0.001] than in patients with admission values 
of serum magnesium 2.6 mg/dl or less. Each mg/dl increase in serum magnesium was associated 
with a decrease in SBP of 4.3 mmHg (95% CI −5.5, −3.1, P <0.001). In addition, 
hypermagnesemic patients had a 2.48-fold greater likelihood (95% CI 2.06, 3.00, P <0.001) of 
receiving intravenous vasopressors during the first 24 h of ICU care, independent of admission 
SBP.
Conclusion—Our findings add support to the biologic importance of magnesium regulation in 
blood pressure control.
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INTRODUCTION
Magnesium, the fourth most abundant intracellular ion, has pleiotropic biologic effects, and 
has been linked to a wide range of diseases, including diabetes [1], insulin resistance [2,3], 
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inflammatory states [4,5], and dyslipidemia [6]. Longstanding and emerging research 
suggests that magnesium also has an important role in vascular biology [7,8], regulating 
vascular tone [9], and cardiac rhythm [10] and contractility [11]. Hypomagnesemia has been 
linked to hypertension in some clinical studies [12,13], but not in others [14–18]. In contrast, 
magnesium infusion induces acute arterial vasorelaxation [19], and chronic magnesium 
supplementation interferes with the downstream effects of aldosterone [20] and attenuates 
development of hypertension [21]. The newly identified families of magnesium transporters, 
including transient receptor potential melastatin (TRPM) [22] expressed in the vasculature 
and the kidney, provide additional mechanistic links to the observed epidemiological 
association between magnesium levels and blood pressure [23].
Little is known about the effect of hypermagnesemia on blood pressure. Small clinical 
studies have suggested that hypotension ensues only at critically high magnesium 
concentrations (3–4 mg/dl), a level rarely seen outside of magnesium intoxication or renal 
failure [24]. In a typical intensive care setting, mild hypermagnesemia is seen in 5–10% of 
patients [25]. A possible relationship between these smaller increases in serum magnesium 
and altered blood pressure has not been previously evaluated.
To assess this question, we examined the association of serum magnesium concentrations 
with SBP and vasopressor requirement in a large sample of patients admitted to a single 
ICU.
METHODS
Study population
We used the Multiparameter Intelligent Monitoring in Intensive Care (MIMIC-II) research 
database, a joint venture of the Laboratory for Computational Physiology at Massachusetts 
Institute of Technology (MIT) and the Department of Medicine at the Beth Israel Deaconess 
Medical Center (BIDMC) [26], a large, urban, academic medical center. The database 
contains data of high temporal resolution obtained from clinical computing systems, 
including lab results, electronic documentation, and bedside monitor trends and waveforms, 
for all patients admitted to BIDMC ICUs between 2001 and 2008. Use of the MIMIC II 
database has been approved by the Institutional Review Boards of Beth Israel Deaconess 
Medical Center and the MIT.
Of the 17 870 unique ICU admissions with an identifiable medication section of the 
discharge summary, 16 054 had documented magnesium concentrations obtained within the 
first 24 h of ICU care. Of these, 472 were missing documentation of SBP. Because of the 
marked effect of renal function on magnesium concentrations, we excluded patients who did 
not have a serum creatinine measurement on both the first and second day of ICU care (n = 
4910), or for whom quantitative documentation of urine output over the first 24 h of ICU 
care was not available (n = 139). Because magnesium is routinely used to treat preeclampsia, 
we excluded all individuals with a diagnosis of preeclampsia or pregnancy-related 
complications (n = 8). An additional four individuals were excluded based on missing 
demographic information, leaving a final sample size of 10 521 unique admissions. Only 
first admissions were used in this analysis.
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Exposure
Magnesium concentrations were taken from the first available laboratory measurement 
recorded within 24 h of admission to the ICU. To limit the effect of outliers, magnesium 
levels were winsorized at the 0.5 and 99.5 percentiles. In addition, we performed analyses 
with magnesium levels dichotomized at 2.6 mg/dl, which is the hospital clinical chemistry 
laboratory’s definition of hypermagnesemia.
Outcome
The primary outcome was the first SBP measured upon arrival to the ICU. Blood pressure 
measurements obtained prior to ICU arrival were not available. As a secondary analysis, we 
examined whether magnesium concentrations were associated with use of vasopressors 
during the first 24 h of ICU care.
Covariates
Demographic information included age, sex, and ethnicity, coded as white, African-
American, Asian, Hispanic, other, or unknown. All 30 comorbidities of the Elixhauser score 
were incorporated into the model as separate, independent measures, rather than a summary 
index score [27]. Individual predictors of illness severity included admission heart rate, 
temperature, and oxygen saturation. Values of serum calcium, phosphate, and hematocrit 
were included when obtained within 24 h of ICU admission. Imputed calculated means 
based on whole data were used for all variables with missing or implausible values: 
temperature (n = 1372), oxygen saturation (n = 1), white cell count (WBC) (n = 13), sodium 
(n = 7), blood urea nitrogen (BUN) (n = 8), calcium (n = 1426), phosphate (n = 1332), and 
hematocrit (n = 59). We also included admission serum creatinine, a follow-up creatinine 
within 24–48 h of ICU admission, and oliguria, defined as a urine output less than 500 
ml/day during the first 24 h of ICU care. In order to describe diuretic exposure, we evaluated 
medications on admission using Natural Language Processing (NLP) of discharge 
summaries. We developed an NLP algorithm that searched for a discrete home medication 
section in the discharge summary and then processed the medications to find individual 
entries of any type of diuretic agent [28].
Statistical analysis
To assess whether SBP was related to magnesium concentrations, we developed sequential 
multivariable linear regression models. Binary indicator variables were created for all 
Elixhauser comorbidities and oliguria. Ethnicity was included as a multicategory variable. 
Age, vital signs, and laboratory values were all included as continuous variables. 
Prehospitalization diuretic exposure was included as a binary variable. We explored 
magnesium both as a continuous variable, and dichotomized at the 2.6 mg/dl threshold. 
Model I included age, sex, and ethnicity. Model II added vital signs, comorbidities, WBC, 
sodium, calcium, phosphate, and hematocrit. Model III added indicators of acute renal 
failure, including admission creatinine and BUN, creatinine within 24–48 h of ICU 
admission, oliguria, and diuretic exposure. We present the mean unadjusted and adjusted 
(model III) admission SBP, with confidence intervals (CIs), by mean serum magnesium 
concentrations on admission.
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Given the dynamic effect of renal function on serum magnesium concentrations, we 
investigated if the association between serum magnesium concentration and blood pressure 
differed as a function of indices of renal function. Indicator variables were created for an 
admission serum creatinine 1.2 mg/dl or less, a creatinine change of above 30% between the 
admission and second day of ICU care, and oliguria. We tested multiplicative interaction 
terms between these variables and magnesium concentrations (defined categorically at 2.6 
mg/dl). To further limit residual confounding by dynamic renal function, we then examined 
the association of hypermagnesemia and SBP in those with static renal function, as defined 
by a creatinine increase between the first and second ICU stay of less than or equal to 10%, 
as well as in those with end-stage renal disease (ESRD), who likely have minimal renal 
function. Chronic dialysis patients were identified by manual review of discharge summaries 
of 473 patients who had a dialysis billing code during their ICU stay, in order to distinguish 
acute from chronic renal failure. Because of the smaller number of ESRD patients, ethnicity 
was recoded into white/nonwhite/ unknown, only congestive heart failure, hypertension, 
diabetes, pulmonary disease, and peripheral vascular disease were included as comorbidity 
variables, and diuretic use was not included in the analysis.
To assess whether magnesium concentrations on admission were associated with 
administration of intravenous vasopressors during the first 24 h of ICU care, we assessed 
vasopressor use, modeled as a binary variable, including all variables used in model III 
above. In addition, we included SBP at the time of ICU admission.
To test the specificity of our model, we also tested our models using admission temperature, 
a physiologic variable associated with critical illness but not hypothesized to relate to serum 
magnesium concentrations.
RESULTS
Admission characteristics
Approximately 6% of patients admitted to the ICU had hypermagnesemia (Table 1). 
Hypermagnesemic patients were older, had a higher prevalence of diuretic use, and had 
worse admission renal function. Both SBP (7 mmHg) and DBP (4 mmHg) were lower in 
hypermagnesemic patients. There was a trend towards a higher prevalence of ESRD amongst 
hypermagnesemic patients.
Association of magnesium with blood pressure
Table 2 presents sequential models of the association between SBP and magnesium, 
modeled categorically or continuously. After adjusting for age, sex, and race (model I), 
hypermagnesemia was strongly associated with lower SBP. The addition of Elixhauser 
comorbidities, vital signs, and other laboratory values slightly attenuated this effect, but it 
remained strong and significant. In the fully adjusted model (model III), SBP at admission 
was 6.2 mmHg lower in hypermagnesemic patients than in individuals with admission 
magnesium concentrations 2.6 mg/dl or less (95% CI −8.2, −4.2, P <0.001). When evaluated 
as a continuous variable, each 1 mg/dl increment in serum magnesium was associated with a 
3.2 mmHg lower SBP (95% CI −4.3, −2.0, P <0.001) when adjusted for age, sex, and race (P 
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<0.001), and a 4.3 mmHg lower SBP (95% CI −5.5, −3.3, P <0.001) in the final 
multivariable adjusted analysis (model III).
The association between magnesium and blood pressure did not seem to differ according to 
renal function. Using model III, we found no evidence of significant multiplicative 
interaction between magnesium above 2.6 mg/dl and the renal function parameters of 
admission creatinine above 1.2 mg/dl, more than 30% increase in serum creatinine between 
the first and second day of ICU care, or oliguria. The unadjusted and adjusted associations 
between magnesium and SBP are illustrated in Fig. 1.
Association of magnesium with blood pressure in patients with static renal function
Because the effect of renal function on magnesium concentrations is difficult to accurately 
quantify in those with dynamic renal function, we studied the association of magnesium 
with blood pressure in two populations whose renal function was static. There were 3497 
patients whose serum creatinine changed 10% or less during the first 2 days of ICU care. 
There were 184 ESRD patients, who likely have minimal residual renal function. Baseline 
characteristics of each group are presented in Table 3. In patients with 10% or less change in 
creatinine, hypermagnesemia was associated with a 9.1 mmHg (95% CI −13.0, −5.2, P 
<0.001) lower SBP in adjusted analysis. In those with ESRD, hypermagnesemia was 
associated with a 16.9 mgHg (95% CI −33.7, −0.60, P = 0.04) lower SBP in adjusted 
analysis.
Association of magnesium with intravenous vasopressor use
Hypermagnesemia was associated with vasopressor use, independent of admission SBP, as 
seen in Table 4. In a fully adjusted model that included admission SBP, hypermagnesemic 
patients had 2.48-fold increased odds of vasopressor administration (95% CI 2.06, 3.00, P < 
0.001) than patients with magnesium concentrations 2.6 mg/dl or less. When analyzed as a 
continuous variable, each 1 mg/dl increase in serum magnesium was associated with a 1.82-
fold adjusted increase in odds of vasopressor use (95% CI 1.62, 2.03, P < 0.001).
Association with temperature as a control
To test the specificity of our analysis, we also evaluated the relationship between magnesium 
concentrations and body temperature at time of admission. No significant association was 
observed between magnesium concentrations modeled continuously and temperature.
DISCUSSION
In this large single-center sample of critically ill patients, hypermagnesemia was associated 
with lower SBP, independent of measured renal function. In addition, hypermagnesemia was 
associated with the administration of intravenous vasopressors during the first 24 h of ICU 
care, independent of admission SBP.
Hypermagnesemia-induced hypotension is well described, but thought to occur at levels of 
serum magnesium not frequently encountered in practice. In our study, mild 
hypermagnesemia was observed in 6% of ICU patients, and was associated with 
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significantly lower SBPs. Most clinical trials on the effect of magnesium supplementation on 
blood pressure have studied the effect of magnesium intake, not achieved serum magnesium 
concentrations. Given that most study participants had normal renal function, magnesium 
supplementation would not be expected to produce frank hypermagnesemia. However, a 
magnesium dosage effect has been suggested [29], and the studies showing positive 
associations [12,14] usually administered higher daily magnesium doses than did the 
negative trials [30–33].
Renal function was, as expected, a strong predictor of serum magnesium concentration. 
Although we attempted to account for renal function in our analyses, without knowledge of 
baseline renal function prior to admission, it is impossible to fully characterize the presence 
of acute renal failure. Furthermore, the challenges of estimating glomerular function from 
serum creatinine, particularly in critical illness where renal function is dynamic, adds 
potential further confounding. By examining those with minimal change in serum creatinine 
during the first 48 h of ICU care, and those with minimal renal function (ESRD), we 
attempted to limit the confounding effect of dynamic renal function on the association of 
magnesium and blood pressure. In both groups, the association of hypermagnesemia with 
lower blood pressure remained robust.
The clinical significance of hypermagnesemia in ESRD has not previously been well 
characterized. In our analysis, almost 10% of ESRD patients were hypermagnesemic, and 
they had a 17 mmHg lower adjusted admission SBP than ESRD patients with magnesium 
concentrations 2.6 mg/dl or less. Hypomagnesemia has been associated with peripheral 
vascular disease in patients with renal failure [34], and magnesium supplementation prevents 
vascular smooth muscle cell calcification [35–37], suggesting that higher levels of 
magnesium may be beneficial in ESRD patients [38]. Conversely, whether 
hypermagnesemia contributes to intradialytic hypotension – a significant problem for many 
dialysis patients – has not been studied.
The ubiquitous distribution and activity of some TRPM magnesium transporters may play a 
role in the observed association of serum magnesium with lower blood pressure. Vascular 
TRPM7 serves as a kinase involved in vascular smooth muscle cell growth, apoptosis, and 
contractility, and as an ion channel that influences intracellular magnesium concentrations 
that suppress calcium channels, blocks inward K currents, and attenuates calcium-
contraction coupling. TRPM6 modulates renal epithelial magnesium transport, and 
mutations have been associated with changes in serum magnesium [39,40]. Thus, although 
gain-of-function mutations or polymorphisms have not yet been described, serum 
magnesium concentrations might simply reflect activity of TRPM channels and/or other 
magnesium transporters and not a direct pathogenic role in blood pressure. In addition, since 
aldosterone and angiotensin II have been associated with decreased TRPM expression 
[41,42], systemic hypertension could itself induce renal magnesium wasting.
Extracellular magnesium has also been shown to alter responses to vasoconstrictor and 
vasodilator agents [43]. The absence of magnesium potentiates the contractile response to 
angiotensin II, whereas magnesium infusion inhibits endothelin-1 vasoconstriction [44]. Our 
findings that hypermagnesemic patients are more likely to receive intravenous vasopressors, 
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independent of admission blood pressure, support a role for the vasoactive effects of 
magnesium.
Limitations of this study include lack of knowledge about over-the-counter medications that 
could influence magnesium concentrations, including magnesium-containing supplements. 
In addition, we had no method to assess for nutritional intake or gastrointestinal loss of 
magnesium. Since we used the first blood pressure entered into the bedside electronic 
medical record, we assume these were likely to be noninvasive measurements, and whether 
invasive measurements would lead to different findings is not known. Finally, since our 
sample is comprised of critically ill patients, generalizability to the outpatient population is 
uncertain.
In conclusion, in this large sample of critically ill patients, hypermagnesemia was associated 
with lower SBP and with the administration of intravenous vasopressors during the first 24 h 
of ICU care. These clinical findings add support to experimental data associating 
magnesium with blood pressure control. However, further well designed studies will be 
required to evaluate additional residual confounding factors that may have influenced the 
associations detected in this large single-center patient group.
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FIGURE 1. 
Unadjusted and model III-adjusted associations between admission serum magnesium 
concentration and initial ICU SBP. Mean, with 95% confidence intervals.
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TABLE 1
Baseline characteristics
Magnesium >2.6 (n = 664) Magnesium ≤2.6 (n = 9857) P-value
Age, mean (SD), (years) 68.1 (14.9) 64.2 (17.6) <0.001
Male, no. (%) 404 (60.8) 5556 (56.4) <0.001
Female, no. (%) 260 (39.2) 4301 (43.6) <0.001
Ethnicity, no. (%)
White 470 (70.8) 6997 (71.0) <0.001
Black or African-American 50 (7.5) 702 (7.1)
Hispanic or Latin 18 (2.7) 267 (2.7)
Asian 13 (2.0) 221 (2.2)
Other 13 (2.0) 237 (2.4)
Unknown 100 (15.1) 1433 (14.5)
Past medical history1, no. (%)
Hypertension 174 (26.2) 3312 (33.6) <0.001
Congestive heart failure 156 (23.5) 2209 (22.4) 0.51
Cardiac arrhythmia 161 (24.3) 2065 (21.0) 0.05
End-stage renal disease 17 (2.6) 167 (1.7) 0.12
Diabetes 195 (29.4) 2464 (25.0) 0.02
Preadmission diuretic use 290 (43.7) 2935 (29.8) <0.001
Vital signs, mean (SD)
SBP (mmHg) 116.8 (23.9) 124.2 (26.5) <0.001
DBP (mmHg) 58.8 (14.6) 63.1 (16.5) <0.001
Heart rate, beats/min 69.8 (19.4) 69.3 (22.1) 0.52
Temperature (°C) 36.5 (0.78) 36.7 (0.95) <0.001
Peripheral oxygen saturation (%) 94.3 (6.6) 93.0 (9.2) <0.001
Admission laboratory values, mean (SD)
White blood cell count (K/µl) 13.2 (6.8) 12.7 (9.9) 0.21
Hematocrit (%) 30.1 (5.9) 32.2 (6.0) <0.001
Sodium (meq/l) 137.3 (5.9) 138.3 (4.8) <0.001
Calcium (mg/dl) 8.4 (0.93) 8.2 (0.87) <0.001
Phosphate (mg/dl) 4.0 (1.6) 3.6 (1.2) <0.001
Urea nitrogen (mg/dl) 37.1 (31.7) 24.5 (19.7) <0.001
Creatinine (mg/dl) 1.8 (1.8) 1.3 (1.3) <0.001
24–48-h creatinine (mg/dl) 1.9 (1.7) 1.3 (1.2) <0.001
Vasopressor use, no. (%) 277 (41.7) 6706 (68.0) <0.001
1
Past medical history as determined by Elixhauser coding.
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TABLE 2
Cross-sectional association between magnesium concentration and SBP
Mean difference in SBP associated with magnesium concentrations
Mg ≤ 2.6 Mg >2.6
Per 1 mg/dl increase in
magnesium concentration
SBP
  Model 1a 1.00 (Ref.) −7.7 (−9.7, −5.6) P < 0.001 −3.2 (−4.3, −2.0) P < 0.001
  Model 2b 1.00 (Ref.) −6.5 (−8.5, −4.5) P < 0.001 −4.7 (−5.8, −3.5) P < 0.001
  Model 3c 1.00 (Ref.) −6.2 (−8.2, −4.2) P < 0.001 −4.3 (−5.5, −3.1) P < 0.001
a
Model 1 adjusts for age, sex, and race.
b
Model 2 adjusts for age, sex, race, all 30 Elixhauser comorbidities, heart rate, temperature, oxygen saturation, WBC, hematocrit, sodium, calcium, 
and phosphate.
c
Model 3 adjusts for age, sex, race, all 30 Elixhauser comorbidities, heart rate, temperature, oxygen saturation, WBC, hematocrit, sodium, calcium, 
phosphate, BUN, creatinine at admission and after 24 h, presence of oliguria, and prehospital diuretic exposure.
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TABLE 3
Baseline characteristics of those with static renal function
Creatinine change
≤ 10% (n = 3497)
End-stage renal
disease (n = 184)
Age (years) 65.0 (17.5) 63.7 (15.0)
Male, no. (%) 2085 (60.0) 113 (61.0)
Admission creatinine (mg/dl) 1.3 (1.4) 6.3 (3.0)
24–48 h creatinine (mg/dl) 1.3 (1.4) 5.9 (2.6)
SBP (mmHg) 126.2 (26.3) 129.8 (33.5)
Hypermagnesemia, no. (%) 179 (5.1) 17 (9.2)
Mean values (SD).
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TABLE 4
Association between serum magnesium concentration and intravenous administration of vasopressors during 
first 24 h of ICU carea
Odds ratio for intravenous vasopressor administration
Mg ≤ 2.6 Mg >2.6
Odds increase per 1 mg/dl increase
in magnesium concentration
Model 1a 1.00 (Ref.) 2.77 (2.38,3.25) P < 0.001 1.65 (1.49, 1.81) P < 0.001
Model 2b 1.00 (Ref.) 2.36 (1.97, 2.83) P < 0.001 1.70 (1.53–1.90) P < 0.001
Model 3c 1.00 (Ref.) 2.48 (2.06, 3.00) P < 0.001 1.82 (1.62–2.03) P < 0.001
a
Model 1 adjust for age, sex, and race.
b
Model 2 adjusts for age, sex, race, all 30 Elixhauser comorbidities, heart rate, temperature, oxygen saturation, admission systolic blood pressure, 
WBC, hematocrit, sodium, calcium, and phosphate.
c
Model 3 adjusts for age, sex, race, all 30 Elixhauser comorbidities, heart rate, temperature, oxygen saturation, admission systolic blood pressure, 
WBC, hematocrit, sodium, calcium, phosphate, BUN, creatinine at admission and after 24 h, presence of oliguria, and prehospital diuretic 
exposure.
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